Skip to main content
SpringerLink
Log in

Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients

  • Articles
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

The purpose of this prospective randomized study was to compare the efficacy and safety of imipenem and cefoperazone-sulbactam combined with vancomycin for the treatment of fever in neutropenic cancer patients. Patients were assigned to either imipenem 500 mg/m2 (500 mg for bone marrow transplant recipients) every 6 h or cefoperazone (2 g)-sulbactam (1 g) every 8 h. All patients received vancomycin 1 g every 12 h. A total of 457 febrile or infectious episodes occurring in 407 patients were entered in the study. The response rate was 73% for imipenem plus vancomycin and 74% for cefoperazone-sulbactam plus vancomycin among the 369 episodes that could be evaluated. Response rates were comparable for the two regimens with regard to infecting organism, administration of antimicrobial prophylaxis, and neutrophil count and trend. The frequency of side-effects was significantly higher for imipenem plus vancomycin (11 % vs. 5%, p = 0.02), due to therapy-associated nausea and vomiting (5.3% vs. 0%, p = 0.0004). The overall frequency of superinfections was similar with both regimens, butClostridium difficile colitis occurred significantly more often in patients receiving imipenem plus vancomycin (5 vs. 0, p = 0.02). In this study cefoperazone-sulbactam plus vancomycin was an effective alternative to imipenem plus vancomycin for initial therapy of fever in neutropenic patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Schimpff SC: Therapy of infection in patients with granulocytopenia. Medical Clinics of North America 1977, 61: 1101–1118.

    PubMed  Google Scholar 

  2. Bodey GP, Nies BA, Mohberg NR, Freireich EJ: Use of gamma globulin in infection in acute leukemia patients. Journal of American Medical Association 1964, 190: 1099–1102.

    Google Scholar 

  3. Pizzo P: Granulocytopenia and cancer therapy: past problems, current solutions, future challenges. Cancer 1984, 54, Supplement: 2649–2661.

    PubMed  Google Scholar 

  4. Ho WG, Winston DJ: Infection and transfusions therapy in acute leukaemia. Clinical Haematology 1986, 15: 873–904.

    Google Scholar 

  5. Pizzo PA, Robicard KJ, Wesley R, Commers J: Fever in the pediatric and young adult patient with cancer: a prospective study of 1001 episodes. Medicine 1982, 61: 153–165.

    PubMed  Google Scholar 

  6. Keating MJ, Bodey GP, Valdivieso M, Rodriguez V: A randomized comparative trial of three aminoglycosides — comparison of continuous infusions of gentamicin, amikacin and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignancies. Medicine 1979, 58: 159–170.

    PubMed  Google Scholar 

  7. Fainstein V, Bodey GP, Bolivar R, Elting L, McCredie KB, Keating MJ: Moxalactam plus ticarcillin or tobramycin in the treatment of febrile episodes in granulocytopenic cancer patients. Archives of Internal Medicine 1984, 144: 1766–1770.

    PubMed  Google Scholar 

  8. Anaissie EJ, Fainstein V, Bodey GP, Rolston K, Elting L, Kantarjian H, Cabanillas F, McCredie KB: Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients. American Journal of Medicine 1988, 84: 581–589.

    PubMed  Google Scholar 

  9. Fainstein V, Bodey GP, Elting L, Bolivar R, Keating MJ, McCredie KB, Valdivieso M: A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. Journal of Antimicrobial Chemotherapy 1983, 12. Supplement A: 101–110.

    Google Scholar 

  10. Pizzo P, Hathorn J, Hiemenz J, Browne M, Commers J, Cotton D, Gress J, Longo D, Marshall D, McKnight J, Rubin N, Skelton J, Thaler M, Wesley R: A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. New England Journal of Medicine 1986, 315: 552–558.

    PubMed  Google Scholar 

  11. Mortimer J, Miller S, Black D, Kwok K, Kirby WE: Comparison of cefoperazone and mezlocillin with imipenem as empiric therapy in febrile neutropenic cancer patients. American Journal of Medicine 1988, 85: 17–20.

    Google Scholar 

  12. De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly P, for the Intercontinental Antimicrobial Study Group: Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. Annals of Internal Medicine 1994, 120: 834–844.

    PubMed  Google Scholar 

  13. Winston DJ, Winston GH, Bruckner DA, Champlin RE: Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Annals of Internal Medicine 1991, 115: 849–859.

    PubMed  Google Scholar 

  14. Rolston KVI, Berkey P, Bodey GP, Anaissie EJ, Khardori NM, Joshi JH, Keating MJ, Holmes FA, Cabanillas FF, Elting L: A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Archives of Internal Medicine 1992, 152: 283–291.

    PubMed  Google Scholar 

  15. Liang R, Yung R, Chiu E, Chau PY, Chan TK, Lam WK, Todd D: Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients. Antimicrobial Agents and Chemotherapy 1990, 34: 1336–1341.

    PubMed  Google Scholar 

  16. Freifeld AG, Walsh T, Marshall D, Gress J, Steinberg SM, Hathorn J, Rubin M, Jarosinski P, Gill V, Young RC, Pizzo PA: Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. Journal of Clinical Oncology 1995, 13: 165–176.

    PubMed  Google Scholar 

  17. English AR, Retsema JA, Girard AE, Lynch JE, Barth WE: CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta lactams: initial bacteriological characterization. Antimicrobial Agents and Chemotherapy 1978, 14: 414–419.

    PubMed  Google Scholar 

  18. Bodey GP, Miller P Ho DH: In vitro assessment of sulbactam plus cefoperazone in the treatment of bacteria isolated from cancer patients. Diagnostic Microbiology and Infectious Diseases 1989, 12, Supplement: 209–214.

    Google Scholar 

  19. Jauregui LE, Appelbaum PC, Fabian TC, Hageage G, Strausbaugh L, Martin LF: A randomized clinical study of cefoperazone and sulbactam versus gentamicin and clindamycin in the treatment of intra-abdominal infections, Journal of Antimicrobial Chemotherapy 1990, 25: 423–433.

    PubMed  Google Scholar 

  20. Horiuchi A, Hasegawa H, Kageyama T, Yonezawa T, Kitani T, Masaoka T, Yasunaga K, Kawagoe H, Nagai I: Efficacy of sulbactam/cefoperazone for the treatment of infections in patients with hematologic diseases. Diagnostic Microbiology and Infectious Diseases 1989, 12, Supplement: 215–219.

    Google Scholar 

  21. Chandrasekar PH, Sluchak JA, Kruse JA: Therapy with cefoperazone plus sulbactam against disseminated infection due to cefoperazone-resistantPseudomonas aeruginosa andEscherichia coli in granulocytopenic mice. Antimicrobial Agents and Chemotherapy 1993, 37: 1927–1930.

    PubMed  Google Scholar 

  22. Bodey GP, Elting LS, Narro J, Koller C, O'Brien S, Estey E, Benjamin R: An open trial of cefoperazone plus sulbactam for the treatment of fever in cancer patients. Journal of Antimicrobial Chemotherapy 1993, 32: 141–152.

    Google Scholar 

  23. Norrby S, Rogers J, Ferber LF, Jones KH, Zacchei AG, Weidner LL, Demetriades JL, Gravallese DA, Hsieh JY-K: Disposition of radiolabeled imipenem and cilastatin in normal human volunteers. Antimicrobial Agents and Chemotherapy 1984, 26: 707–714.

    PubMed  Google Scholar 

  24. Elting LS, Bodey GP, Keefe BH: Septicemia and shock syndrome due to viridans streptococci: a case controlled study of predisposing factors. Clinical Infectious Diseases 1992, 14: 1202–1207.

    Google Scholar 

  25. Bodey GP, Elting L, Jones P, Alvarez ME, Rolston K, Fainstein V: Imipenem/cilastatin therapy of infections in cancer patients. Cancer 1987, 60: 255–262.

    PubMed  Google Scholar 

  26. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958, 53: 457–481.

    Google Scholar 

  27. Koll BS, Brown AE: The changing epidemiology of infections at cancer hospitals. Clinical Infectious Diseases 1993, 17, Supplement 2: 322–327.

    Google Scholar 

  28. Johnson AP, Uttley AHC, Woodford N, George RC: Resistance to vancomycin and teicoplanin: an emerging clinical problem. Clinical Microbiology Reviews 1990, 3: 280–291.

    PubMed  Google Scholar 

  29. Bodey GP: Candidiasis in cancer patients. American Journal of Medicine 1984, 77, Supplement 4D: 13–19.

    Google Scholar 

  30. Stone HH, Kolb LD, Currie CA, Geheber CE, Cuzzel JZ:Candida sepsis: pathogenesis and principles of treatment. Annals of Surgery 1974, 179: 697–711.

    PubMed  Google Scholar 

  31. Kennedy MJ, Volz PA: Effect of various antibiotics on gastrointestinal colonization and dissemination byCandida albicans. Sabouraudia 1985, 23: 265–273.

    PubMed  Google Scholar 

  32. Michea-Hamzehpour M, Aukenthaler MR, Junz J, Pechere JC: Effect of a single dose of cefotaxime or ceftriaxone on human fecal flora. A double-blind study. Drugs 1988, 35, Supplement 2: 6–11.

    Google Scholar 

  33. Seelig MS: Mechanisms by which antibiotics increase the incidence and severity of candidiasis and alter the immunological defenses. Bacteriological Reviews 1966, 30: 442–459.

    PubMed  Google Scholar 

  34. Samonis G, Anaissie EJ, Bodey GP: Effects of broadspectrum antimicrobial agents on yeast colonization of the gastrointestinal tracts of mice. Antimicrobial Agents and Chemotherapy 1990, 34: 2420–2422.

    PubMed  Google Scholar 

  35. Samonis G, Gikas A, Anaissie EJ, Vrenzos G, Maraki S, Tselentis Y, Bodey GP: Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans. Antimicrobial Agents and Chemotherapy 1993, 37: 51–53.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Specialties, Section of Infectious Diseases, University of Texas, M.D. Anderson Cancer Center, 1515, Holcombe Boulevard, 77030, Houston, Texas, USA

    G. Bodey, D. Abi-Said, K. Rolston, I. Raad & E. Whimbey

Authors
  1. G. Bodey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Abi-Said
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Rolston
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Raad
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Whimbey
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bodey, G., Abi-Said, D., Rolston, K. et al. Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients. Eur. J. Clin. Microbiol. Infect. Dis. 15, 625–634 (1996). https://doi.org/10.1007/BF01691147

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01691147

Keywords

Search

Navigation